Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca

Mark Dewhirst

Status

Withdrawn

Conditions

Ovarian Cancer

Treatments

Device: Hyperthermia

Study type

Interventional

Funder types

Other

Identifiers

NCT00787488

Pro00008510

Details and patient eligibility

About

This is a pilot study aimed to test the feasibility and safety of administering combination chemotherapy with paclitaxel (both intravenously and intraperitoneally) and cisplatin (intraperitoneally) plus whole abdominal hyperthermia every 3 weeks in the treatment of optimally debulked, advanced or recurrent ovarian, primary peritoneal, and fallopian tube cancer patients.

Full description

Day 1 of each 21 day Cycle:

Paclitaxel 175 mg/m2 IV (infused over 3 hours)

Day 1 or 2 of each Cycle Adequate IV hydration with normal saline (1000 ml recommended)followed by intraperitoneal infusion of 500 ml normal saline through the IP port.

Cisplatin 75 mg/m2 reconstituted in 500 ml NS warmed to 37 degrees Celsius is infused IP (30 minute infusion)followed immediately by whole abdominal hyperthermia

Abdominal hyperthermia will be delivered using the BSD 2000 ellipse system to target temperatures of 40-42 degrees Celsius monitored via rectally and vaginally continuing for no greater than 60 minutes after maximal 30 minute warm-up phase. Total duration of hyperthermia will be no greater than 90 minutes.

Day 8:

Paclitaxel 60 mg/m2 IP. Paclitaxel will be diluted and filtered initially in 1000 ml of normal saline or D5W warmed to 37 degrees Celsius. For IP administration, the patient must receive an additional 1000 ml of normal saline degrees Celsius in the peritoneal cavity.

Cycles will be repeated every 3 weeks x 6 cycles. Patients will be followed until disease progression/recurrence or death.

Sex

Female

Ages

18 to 72 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically diagnosed Stage III or Stage IV advanced, persistent, or recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
Optimal debulking (< 1cm residual disease) of their disease within 6 weeks of the start of the study
Patients must have received no more than 2 prior chemotherapy regimens with at least 4 weeks since prior chemotherapy
GOG performance status 0, 1, or 2
Patients must have normal organ and marrow function defined as:
absolute neutrophil count >1,500/mcL
platelets >100,000/mcL
total bilirubin and creatinine <1.5 X institutional upper limit of normal(ULN)
AST(SGOT)/ALT(SGPT)<3 X institutional ULN

Exclusion criteria

Patients with biochemical recurrences or evidence of measurable disease
Patients with suboptimal (>1 cm) residual disease
Patients who have had chemotherapy within 4 weeks prior
Receiving any investigational agents
Known brain metastases
Epithelial ovarian carcinoma of low malignant potential (borderline carcinomas)
Uncontrolled intercurrent illness
Prior radiation therapy
History of other invasive or pre-invasive malignancies (except non-melanoma skin cancer) within the past 5 years